Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • AstraZeneca and Merck decision to disinvest in the UK is a ‘tragedy’ for British research and innovation

    September 17, 2025 | AstraZeneca, Merck, clinical trials, patient recruitment 

    Kate Shaw comments on the latest news about AstraZeneca and Merck’s decision to hold planned investments in the UK

    - PMLiVE

    The recent decision by pharmaceutical company AstraZeneca to pause a planned £200 million expansion of its Cambridge research site and the announcement by Merck (known as MSD in Europe) to withdraw its life science research operation from the UK have been described as a ‘tragedy’ by Innovative Trials’ founder and CEO, Kate Shaw.

     

    Read more here: https://innovativetrials.com/astrazeneca-and-merck-decision-to-disinvest-in-uk-is-a-tragedy-for-british-research-and-innovation-says-innovative-trials/

    This content was provided by Innovative Trials

    Company Details

    - PMLiVE

    Innovative Trials

    Email
    Website

     Latest Content from  Innovative Trials 

    Accelerating patient recruitment in clinical trials post COVID-19

    Patient recruitment is arguably one of the most important aspects of a clinical trial. Without enough participants, trials will inevitably fail, meaning potentially effective therapies will not be brought to...

    Diversity in Clinical Trials: A more inclusive approach in patient recruitment

    We have seen a growing focus on patient diversity in clinical trials in recent years, but the COVID-19 vaccine trials in particular have highlighted the importance of achieving diverse patient...

    Innovative Trials partners with MS Society

    UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis

    FREE Live Webinar – Accelerating Patient recruitment in Clinical Trials post COVID-19 – 8th June 2022

    Innovative Trials and Parexel invite you to attend the live webinar

    Innovative Trials named a finalist in the Inspiring Hertfordshire Awards

    The patient recruitment organisation has been shortlisted in the Inspiring Hertfordshire awards

    Innovative Trials suspends services in Russia in response to Ukraine war

    Kate Shaw, Founder & CEO of the leading patient recruitment organisation based in Letchworth (UK), on the current Russia-Ukraine situation.

    Improving diversity in clinical trial patient recruitment

    A key requirement for clinical trials is to understand the effect of potential treatments on the patient populations that will benefit most. Despite this, many studies find diverse patient recruitment...

    Increasing patient randomisation rate by 200% for a Top 5 global pharma

    Phase IIa Moderate to Severe Hidradenitis Suppurativa Case Study

    Eating Disorders Awareness Week

    In the latest blog post, Innovative Trials' Equality & Diversity committee focuses on eating disorders

    FREE Live Webinar – Diversity in Clinical Trials – 24th February

    Innovative Trials, Pfizer and Parexel invite you to attend the live webinar